
Genetic epilepsy with febrile seizures plus (GEFS+) is a genetic epilepsy syndrome characterized by a marked hereditary tendency inherited as an autosomal dominant trait. Patients with GEFS+ may develop typical febrile seizures (FS), while generalized tonic–clonic seizures (GTCSs) with fever commonly occur between 3 months and 6 years of age, which is generally followed by febrile seizure plus (FS+), with or without absence seizures, focal seizures, or GTCSs. GEFS+ exhibits significant genetic heterogeneity, with polymerase chain reaction, exon sequencing, and single nucleotide polymorphism analyses all showing that the occurrence of GEFS+ is mainly related to mutations in the gamma-aminobutyric acid type A receptor gamma 2 subunit (GABRG2) gene. The most common mutations in GABRG2 are separated in large autosomal dominant families, but their pathogenesis remains unclear. The predominant types of GABRG2 mutations include missense (c.983A → T, c.245G → A, p.Met199Val), nonsense (R136*, Q390*, W429*), frameshift (c.1329delC, p.Val462fs*33, p.Pro59fs*12), point (P83S), and splice site (IVS6+2T → G) mutations. All of these mutations types can reduce the function of ion channels on the cell membrane; however, the degree and mechanism underlying these dysfunctions are different and could be linked to the main mechanism of epilepsy. The γ2 subunit plays a special role in receptor trafficking and is closely related to its structural specificity. This review focused on investigating the relationship between GEFS+ and GABRG2 mutation types in recent years, discussing novel aspects deemed to be great significance for clinically accurate diagnosis, anti-epileptic treatment strategies, and new drug development.
假性甲状旁腺功能减退症(Pseudohypopara-thyroidism,PHP)是甲状旁腺功能减退症的一种少见类型,是一种罕见的、遗传性疾病,由甲状旁腺激素(Hypoparathyroidism,PTH)抵抗引起,导致低钙血症、高磷血症和甲状旁腺激素水平升高[1].
吡仑帕奈是一种新型抗癫痫发作药物,属于非竞争性选择性α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(a-amino-3hydroxyl-5-methyl-4-isoxazolepropiona-teacid,AMPA)受体拮抗剂,它通过靶向突触后膜谷氨酸活动,抑制兴奋性神经传递,从而发挥抗癫痫发作作用[1].2021年7月,吡仑帕奈在中国获批用于成人和4岁以上儿童局灶性癫痫(伴或不伴继发全面性发作)的单药及添加治疗[2].美国和日本此前已经批准该适应证,但欧洲用于4岁以上癫痫局灶性发作患者时仍限于添加治疗[3-5].
目的 研究4种环状RNA(circular RNA,circRNA)在癫痫患者外周血单个核细胞(Peripheral blood mononuclear cell,PBMC)中的表达及运用生物信息学进行功能预测,为癫痫的发病机制探究提供依据.方法 选取2020年5月-2021年5月于内蒙古科技大学包头医学院第一附属医院神经内科诊治的癫痫患者22例,其中男13例、女8例,平均年龄(36.41±8.39)岁;健康对照组22名,男、女各11名,平均年龄(34.41±8.68)岁.采用实时荧光定量 PCR 法检测 PBMC 中的 circRNA:EFCAB2、C14orf159、PARG、TMEM39的表达水平并利用生物信息学对其功能进行预测.结果 相比对照组,EFCAB2和C14orf159两种circRNA在癫痫患者外周血PBMC中明显升高,EFCAB2相对表达为1.42±0.06(t=29.41),C14orf159相对表达为1.31±0.03(t=25.27),PARG、TMEM39在外周血PBMC中未检测到.生物信息学分析显示EFCAB2得到的三个微小 RNA(micro RNA,miRNA):miR-6873-3p、miR-6739-3p、miR-7110-3p;C14orf159得到的三个 miRNA:miR-1180-3p、miR-6501-3p、miR-3622b-5p.通过 TargetScan 数据库对癫痫相关的基因进行预测,EFCAB2:miR-6873-3p符合条件的共有11个下游基因;miR-6739-3p符合条件的共有7个下游基因;miR-7110-3p符合条件的共有14个下游基因.C14orf159:miR-6501-3p符合条件的共有9个下游基因;miR-3622b-5p符合条件的共有14个下游基因;miR-1180-3p符合条件的共个1下游基因.结论 研究表明EFCAB2和C14orf159两种circRNA可能是癫痫的重要生物学标志物,通过生物信息学分析,这两种circRNA可能具备充当"分子海绵"调控癫痫.EFCAB2具备充当miR-6873-3p和miR-7110-3p"分子海绵"的潜能,同时发现miR-6873-3p和miR-7110-3拥有共同的下游靶基因MAP1B-通过调控电压门控钠通道在癫痫中发挥作用;C14orf159可以充当miR-6501-3p的分子海绵从而调控CCL3的表达在癫痫中发挥作用.
目的 研究莆田地区癫痫患儿在长期使用丙戊酸钠(Sodium valproate,VPA)治疗过程肝功能变化等的相关性,探讨临床用药过程中进行个体化给药进而提升临床患儿用药依从性的方法及依据.方法 回顾性分析350例于2018年6月1日-2021年3月1日期间在莆田学院附属医院单用丙戊酸钠治疗的0~14岁癫痫患儿的丙戊酸钠血药浓度及相关生化检测的数据,按照VPA血药浓度结果分为低血药浓度组(<50 μg/mL)、治疗血药浓度组(50~100 μg/mL)和高血药浓度组(>100 μg/mL).随机抽取350名同期在我院健康查体的0~14岁儿童的生化常规作为对照组.结果 ①VPA治疗组与对照组肝功能指标均无统计学差异(P>0.05);②各VPA血药浓度范围组间肝功能谷丙转氨酶、谷草转氨酶、谷草转氨酶/谷丙转氨酶、总胆红素和直接胆红素存在统计学差异(P<0.05);③高浓度血药浓度的肝功能指标异常发生率较低浓度、治疗浓度组高,且存在差异(P<0.05).结论 肝功能异常在高血药浓度治疗组中较常见,应及时调整患儿用药剂量以避免药导致的肝损伤.